OakChart

VivoSim Labs Inc

VIVSHealthcare·Biotechnology·USA·Nano·NASD·Nov 12 • 6:03 AM ET

0.1562+0.0016 (1.03%)
2026-11-12 12:10 CET
Market cap
2.56 USD m
Revenue, TTM
0.11 USD m
Net income, TTM
-12.34 USD m
Free cash flow, TTM
-10.12 USD m
EPS diluted, TTM
-4.47
P/E
-
Compare

Price

VIVS against its 20, 50 and 200-day averages
2050200
Patternshover a marker to name it
Sales mean, own scale0–100
RS 2Sales 0.04Price0.040.501.001.502.0057.7M115.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26VIVSclose 0.1620-day 0.1550-day 0.20200-day 0.990.16

95.4% under the 52-week high of 3.40 on 30 Jan 2026. 52-week low 0.12 on 10 Nov 2026. Last 15 sessions, 46.0% high to low

Volume 0.25× normal · the line is the 50-bar volume average

Profile

VIVS
52-week range, 1% of the way up
0.123.40

VivoSim Labs, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.

Employees15
IPOFeb 14, 2012
Beta1.55
ATR, 14d0.02
Rel volume0.25
Short float4.70%
Insider own16.62%
Inst own11.17%

Snapshot

6 groups

Valuation

Index-
Market Cap2.59M
Enterprise Value1.24M
Income-12.34M
Sales0.11M
Book/sh-0.73
Cash/sh0.10
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees15
IPOFeb 14, 2012

Ratios

P/E-
Forward P/E-
PEG-
P/S23.51
P/B-
P/C1.55
P/FCF-
EV/EBITDA-
EV/Sales11.24
Quick Ratio1.70
Current Ratio1.70
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-4.47
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y39.18% 28.81%
Sales past 3/5Y-29.26% -
EPS Y/Y TTM-194.95%
Sales Y/Y TTM-21.13%
EPS Q/Q77.51%
Sales Q/Q-51.35%
Earnings-
EPS/Sales Surpr.46.15% -26.83%

Ownership

Insider Own16.62%
Insider Trans0.36%
Inst Own11.17%
Inst Trans0.46%
ROA-155.93%
ROE-343.10%
ROIC-
Gross Margin-73.21%
Oper. Margin-10116.96%
Profit Margin-11016.07%
SMA202.54%
SMA50-20.98%
SMA200-84.28%
Trades-

Technical

Shs Outstand16.59M
Shs Float13.83M
Short Float4.70%
Short Ratio0.63
Short Interest0.65M
52W High3.40 -95.41%
52W Low0.12 25.97%
Volatility17.38% 12.65%
ATR (14)0.02
RSI (14)45.36
Beta1.55
Rel Volume0.25
Avg Volume1.03M
Volume12,730

Performance

Perf Week10.39%
Perf Month-2.92%
Perf Quarter-51.57%
Perf Half Y-88.17%
Perf YTD-91.37%
Perf Year-93.09%
Perf 3Y-99.04%
Perf 5Y-99.77%
Perf 10Y-99.98%
Recom3.00
Target Price64.80
Prev Close0.15
Price0.16
Change %1.03%

Analyst ratings

latest 6 of 6
DateActionAnalystRating changeTargetImplied
Dec 13, 2018InitiatedHH.C. WainwrightBuy$2.50+1,500.5%
Nov 10, 2017DowngradeRRaymond JamesOutperform → Mkt Perform
Jan 25, 2017InitiatedRRaymond JamesOutperform
Aug 11, 2015DowngradeCCantor FitzgeraldBuy → Hold
Jun 29, 2015InitiatedPPiper JaffrayOverweight$5+3,101.0%
Jun 29, 2015InitiatedJJefferiesBuy$5+3,101.0%

Peers

Mkt cap
TickerCompanyMkt cap
CSBRChampions Oncology Inc66.53M
ABSIAbsci Corp1.72B
CRLCharles River Laboratories International Inc16.53B
LTRNLantern Pharma Inc7.18M
CERTCertara Inc1.80B
ISPCiSpecimen Inc1.79M
HBIOHarvard Bioscience Inc44.50M
MEDPMedpace Holdings Inc18.64B
LABStandard BioTools Inc253.85M
QTRXQuanterix Corp143.38M

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Lialin Tony SergeChief Commercial OfficerAug 31 '26Buy0.2810,0002,80410,000Sep 01 04:01 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • VivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual Meeting (GlobeNewswire) -9.73%
  • VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test (GlobeNewswire) -6.33%
  • VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling (GlobeNewswire)
  • VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods (GlobeNewswire) -5.15%
  • VivoSim Labs Unveils New NAMkind Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs (GlobeNewswire)
  • VivoSim Labs to Add Rat Liver Model to NAMkind Platform (GlobeNewswire)
  • VivoSim: Fiscal Q1 Earnings Snapshot (Associated Press) -5.81%
  • VivoSim Provides Financial and Listing Compliance Update (GlobeNewswire) -9.24%
  • VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS) (InvestorsHub) -10.87%
  • VivoSim Enters China with First Commercial Sales of NAMkind Toxicology Screening and Efficacy Testing Services (GlobeNewswire)
  • VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor (GlobeNewswire) -28.06%
  • VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth (InvestorsHub)
  • VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027 (GlobeNewswire)
  • VivoSim: Fiscal Q4 Earnings Snapshot (Associated Press)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2024Q22024-11-07-1.680-3.120-0.030.041
2024Q12024-08-08-2.760-2.760-2.7370.040.041
2023Q42024-05-23-3.360-3.720-3.6260.030.121
2023Q32024-02-13-4.320-4.320-4.7440.120.121
2023Q22023-11-09-4.320-5.160-5.4970.100.001
2019Q22019-11-07-12.000-14.400-11.5871.230.791
2019Q12019-08-08-12.000-14.400-11.9620.670.701
2018Q42019-05-22-14.400-13.601-14.0280.680.76-
2018Q32019-02-07-14.400-15.840-13.2100.780.85-
2018Q22018-11-09-12.000-16.200-12.2880.940.92-
2018Q12018-11-08-16.800-16.800-16.8000.691.32-
2017Q42018-06-08-16.800-16.800-16.8001.111.32-
2017Q32018-02-08-16.800-22.399-16.8001.151.25-
2017Q22017-11-09-21.600-24.000-21.6001.361.38-
2017Q12017-08-09-21.600-24.000-24.0000.990.94-
2016Q42017-06-07-24.000-25.800-24.0000.810.76-

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2013FY-84.000--84.0000.38-
2014FY-91.200-88.800-91.2000.570.60
2015FY-103.2-106.8-103.21.481.27
2016FY-93.600-95.400-93.6004.234.15
2017FY-76.800-79.200-76.8004.604.80
2018FY-48.000-53.600-55.4043.113.20
2023FY-19.200-16.920-4.6000.110.44
2024FY--9.240-1.700-0.17
2025FY--9.000-5.348-0.20
2026FY--9.000--0.23

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2024Q3S2025-02-101000.040.040.04
2024Q3S2025-02-091000.040.040.04
2024Q3S2025-02-081000.040.040.04
2024Q3S2025-02-071000.040.040.04
2024Q3S2025-02-061000.040.040.04
2024Q3S2025-02-051000.040.040.04
2024Q3S2025-02-041000.040.040.04
2024Q3S2025-02-031000.040.040.04
2024Q3S2025-02-021000.040.040.04
2024Q3S2025-02-011000.040.040.04
2024Q3S2025-01-311000.040.040.04
2024Q3S2025-01-301000.040.040.04
2024Q3S2025-01-291000.040.040.04
2024Q3S2025-01-281000.040.040.04

Estimate history

EPS, annual-76.8-55.404-34.661-29.254-15.784-23.77-19.251-1.7-5.348-4.4717
Period201720182019202020212022202320242025TTM
EPS, quarterly-2.737-1.7-2.2913.61-1.136-0.977-1.032-2.208-0.255
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Sales, annual4.6033.0912.19601.50.370.1090.1440.1310.11
Period201720182019202020212022202320242025TTM
Sales, quarterly0.0390.030.0240.0510.0370.0280.0260.040.018
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Shares, annual0.4630.5170.5440.7230.7260.7260.841.8982.8953.194
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.1981.281.4281.8982.62.6082.6082.8953.194
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.110.130.140.110.371.500.002.203.09
Cost of Goods Sold Incl. D&A0.190.210.270.280.290.140.041.471.47
Gross Profit-0.08-0.08-0.13-0.170.081.36-0.040.731.63
Selling, General and Administrative Excl. Other11.2511.4012.4914.9117.8112.8413.9819.4728.90
Research and Development4.143.994.805.278.723.211.085.0514.20
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-11.33-11.49-12.62-15.09-17.73-11.48-14.02-18.75-27.27
Interest Expense-0.010.010.000.000.000.000.000.00
Unusual Expense-1.400.000.000.000.000.002.812.20-
Net Income Before Taxes-12.33-13.84-2.49-14.67-17.26-11.45-16.82-18.71-26.63
Income Taxes0.010.000.000.000.000.000.000.000.00
Consolidated Net Income-12.34-13.84-2.49-14.67-17.26-11.45-16.83-18.71-26.64
Net Income From Continuing Operations-12.34-13.84-2.49-14.67-17.26-11.45-16.83-18.71-26.64
Net Income-12.34-13.84-2.49-14.67-17.26-11.45-16.83-18.71-26.64
EPS (Recurring)-2.54-5.35-1.70-19.25-23.77-15.78-25.84-31.80-55.40
EPS (Basic, Before Extraordinaries)-4.47-5.35-1.70-19.25-23.77-15.78-29.25-34.66-55.40
EPS (Diluted)-4.47-5.35-1.70-19.25-23.77-15.78-29.25-34.66-55.40
EBITDA-11.14-11.27-12.35-14.81-17.44-11.34-13.98-17.61-26.29
Non-Operating Income (Expense)-2.39-2.3410.140.420.470.030.002.240.64
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.270.240.421.191.881.654.063.004.10
Price To Sales Ratio50.0628.2522.7786.4251.5721.82-24.1937.03
Gross Margin-73.21-64.12-88.19-156.8820.8190.53-33.0652.60
Operating Margin-10,116.96-8,768.70-8,761.11-13,840.37-4,792.16-765.27--853.73-882.37
Net Margin-11,016.07-10,567.18-1,727.78-13,459.63-4,664.59-763.20--852.00-861.70
Shares Outstanding3.192.891.900.840.730.730.720.540.52
Market Capitalization2.562.563.8110.1319.0932.7583.5853.53116.83

Income statement, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q2
Total Revenue0.020.040.030.030.040.050.020.03
Cost of Goods Sold Incl. D&A0.040.040.050.060.060.060.070.07
Gross Profit-0.02-0.00-0.03-0.03-0.02-0.01-0.04-0.04
Selling, General and Administrative Excl. Other2.743.182.722.602.893.143.422.57
Research and Development1.101.091.090.870.940.801.720.93
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.76-3.19-2.75-2.63-2.92-3.15-3.47-2.61
Interest Expense0.000.000.00-0.000.010.01-
Unusual Expense-1.400.000.000.000.000.000.000.00
Net Income Before Taxes-1.33-5.76-2.69-2.54-2.846.85-3.45-2.55
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.34-5.76-2.69-2.54-2.846.85-3.45-2.55
Net Income From Continuing Operations-1.34-5.76-2.69-2.54-2.846.85-3.45-2.55
Net Income-1.34-5.76-2.69-2.54-2.846.85-3.45-2.55
EPS (Recurring)-0.44-2.21-1.03-0.98-1.143.61-2.29-1.70
EPS (Basic, Before Extraordinaries)-0.26-2.21-1.03-0.98-1.143.61-2.29-1.70
EPS (Diluted)-0.26-2.21-1.03-0.98-1.143.61-2.29-1.70
EBITDA-2.72-3.14-2.70-2.58-2.85-3.09-3.40-2.54
Non-Operating Income (Expense)0.03-2.570.060.090.0810.010.030.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.070.090.050.060.080.070.130.15
Price To Earnings Ratio-3.07------
Price To Sales Ratio50.0628.5033.2454.3325.9229.5368.0788.92
Gross Margin-122.22-7.50-100.00-110.71-64.86-19.61-187.50-133.33
Operating Margin-15,327.78-7,967.50-10,576.92-9,410.71-7,878.38-6,184.31-14,450.00-8,693.33
Net Margin-7,433.33-14,410.00-10,350.00-9,089.29-7,683.7813,435.29-14,362.50-8,496.67
Shares Outstanding3.192.892.612.612.601.901.431.28
Market Capitalization2.563.734.727.593.823.817.887.82

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments5.0211.312.9016.0128.6837.3627.3636.4843.73
Short Term Receivables1.050.030.030.150.000.000.110.561.03
Inventories0.000.000.300.000.000.000.000.490.84
Other Current Assets0.560.790.700.890.861.030.851.051.16
Total Current Assets6.6312.133.9417.0529.5338.4028.3238.5746.76
Net Property, Plant & Equipment0.611.291.972.612.810.380.001.832.79
Total Investments and Advances0.140.140.140.140.140.110.000.080.13
Long-Term Note Receivable0.001.00-------
Intangible Assets-0.010.010.010.090.110.120.140.15
Deferred Tax Assets0.12--------
Other Assets0.000.090.290.500.710.920.000.000.00
Total Assets7.5014.656.3520.3133.3039.9228.4440.6249.83
Short Term Debt Incl. Current Port. of LT Debt0.560.650.510.490.480.000.000.000.00
Accounts Payable1.021.640.630.330.410.280.720.630.46
Other Current Liabilities1.201.440.732.850.490.441.093.114.19
Total Current Liabilities2.793.741.863.671.380.721.813.744.66
Long Term Debt0.000.420.891.311.700.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.12--------
Other Liabilities5.700.000.000.000.000.000.000.590.58
Total Liabilities8.604.162.754.983.090.721.814.335.24
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-1.1010.493.6015.3330.2139.2026.6336.3044.59
Total Shareholders Equity-1.1010.493.6015.3330.2139.2026.6336.3044.59
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-1.1010.493.6015.3330.2139.2026.6336.3044.59
Total Liabilities & Stockholders Equity7.5014.656.3520.3133.3039.9228.4440.6249.83
Book Value Per Share-0.385.534.2921.1041.6254.2548.9570.2596.37
Tangible Book Value Per Share-0.385.534.2821.0841.4954.1048.7369.9896.05
Full-Time Employees1513202418966175
Price to Book Ratio-0.218.791.641.251.082.132.013.272.32
Return on Assets-124.98-23.70-110.05-64.39-31.27-49.23-54.18-58.89-58.49
Return on Equity-294.75-35.31-155.00-75.80-32.99-51.12-59.46-65.86-65.08
Return on Invested Capital--22.80-326.82-103.71-35.87-42.93-70.26-73.38-78.06
Quick Ratio2.383.251.964.6421.3553.2615.6510.199.86
Current Ratio2.383.252.124.6421.3553.2615.6510.3210.04

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-12.34-13.84-2.49-14.67-17.26-11.45-16.83-18.71-26.64
Depreciation0.190.210.270.280.290.140.041.140.98
Other Funds (Non Cash)2.123.50-8.281.352.252.265.583.685.26
Funds from Operations-10.03-10.13-10.50-13.04-14.71-9.05-11.21-13.88-20.40
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.07-0.691.04-1.622.310.60-2.11-1.000.02
Cash from Operating Activities-10.10-10.83-9.46-14.65-12.41-8.45-13.32-14.88-20.38
Capital Expenditures-0.020.00-0.01-0.04-0.40-0.41-0.410.00-0.08
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.010.750.00
Purchase or Sale of Investments0.090.099.040.14-0.570.000.000.000.00
Purchase of Investments0.000.00-2.96-10.86-10.950.000.000.000.00
Sale Or Maturity of Investments0.090.0912.0011.0010.380.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.720.000.000.000.000.00
Cash from Investing Activities0.070.099.030.82-0.97-0.41-0.390.75-0.08
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock3.004.818.851.440.000.2523.845.0013.38
Repurchase of Common Pref Stock0.000.000.000.000.000.00-0.000.000.00
Sale of Common Pref Stock3.004.818.851.440.000.2523.845.0013.38
Proceedsfrom Stock Options3.004.818.851.440.000.2523.805.0013.33
Issuance or Reduction of Debt, Net-0.35-0.360.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.05-0.00-0.06-0.22
Other Financing Activities Uses0.000.000.000.000.00-0.05-0.00-0.06-0.22
Cash from Financing Activities2.644.458.851.440.000.2023.844.9313.15
Exchange Rate Effect--------0.00
Net Change in Cash-7.38-6.298.41-12.40-13.37-8.6610.12-9.20-7.30
Free Cash Flow-10.12-10.83-9.47-14.70-12.80-8.86-13.73-14.88-20.45
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Cash & Short Term Investments1.675.024.296.689.0511.31
Short Term Receivables1.041.051.040.030.030.03
Inventories0.000.000.000.000.000.00
Other Current Assets0.510.560.710.880.590.79
Total Current Assets3.236.636.047.599.6812.13
Net Property, Plant & Equipment0.480.610.770.941.111.29
Total Investments and Advances0.140.140.140.140.140.14
Intangible Assets-----0.01
Deferred Tax Assets-0.12----
Other Assets0.000.000.000.000.040.09
Total Assets3.857.506.969.6911.9814.65
Short Term Debt Incl. Current Port. of LT Debt0.320.560.770.880.520.65
Accounts Payable0.621.020.670.580.671.64
Other Current Liabilities0.961.201.040.990.941.44
Total Current Liabilities1.892.792.482.452.143.74
Long Term Debt0.000.000.040.170.300.42
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities-0.12----
Other Liabilities4.305.700.000.000.000.00
Total Liabilities6.198.602.522.622.444.16
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-2.35-1.104.447.079.5410.49
Total Shareholders Equity-2.35-1.104.447.079.5410.49
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-2.35-1.104.447.079.5410.49
Total Liabilities & Stockholders Equity3.857.506.969.6911.9814.65
Book Value Per Share-0.73-0.381.702.713.675.53
Tangible Book Value Per Share-0.73-0.381.702.713.675.53
Full-Time Employees-15---13
Price to Book Ratio-0.210.840.670.800.278.79
Return on Assets-155.93-124.98-22.71-24.12-18.53-23.70
Return on Equity-343.10-294.75-51.07-36.91-24.53-35.31
Return on Invested Capital---60.00-35.17-28.9062.79
Quick Ratio1.702.382.443.104.523.25
Current Ratio1.702.382.443.104.523.25

Cash flow, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Net Income-1.34-5.76-2.69-2.54-2.846.85
Depreciation0.040.040.050.060.060.06
Other Funds (Non Cash)-1.192.950.180.180.19-9.48
Funds from Operations-2.49-2.77-2.46-2.30-2.60-2.56
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.720.540.19-0.07-1.340.53
Cash from Operating Activities-3.21-2.24-2.27-2.38-3.94-2.04
Capital Expenditures-0.020.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.090.000.000.009.00
Purchase of Investments0.000.000.000.000.00-0.50
Sale Or Maturity of Investments0.000.090.000.000.009.50
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.020.090.000.000.009.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.003.000.000.001.813.19
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.003.000.000.001.813.19
Proceedsfrom Stock Options0.003.000.000.001.813.19
Issuance or Reduction of Debt, Net-0.12-0.12-0.120.00-0.130.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.122.88-0.120.001.683.19
Net Change in Cash-3.350.74-2.39-2.38-2.2610.15
Free Cash Flow-3.24-2.24-2.27-2.38-3.94-2.04

Revenue breakdown

Product2024: 25.00K
Royalty2024: 119.00K 2025: 131.00K
United States2024: 144.00K 2025: 131.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.70%0.6M13.8M2.75M
2026-10-154.33%0.6M13.8M4.06M
2026-09-305.12%0.7M13.8M5.81M
2026-09-154.08%0.6M13.8M5.70M
2026-08-315.11%0.7M13.8M5.54M
2026-08-145.23%0.8M14.4M5.49M
2026-07-313.87%0.6M14.7M3.56M
2026-07-151.59%0.0M3.1M1.95M
2026-06-305.00%0.1M2.3M71.92K
2026-06-150.88%0.0M2.3M70.46K
2026-05-291.46%0.0M2.3M70.99K
2026-05-151.77%0.0M2.3M78.22K
2026-04-302.32%0.1M2.3M138.23K
2026-04-151.23%0.0M2.3M1.67M
2026-03-313.55%0.1M2.6M1.67M
2026-03-130.58%0.0M2.6M1.65M
2026-02-271.28%0.0M2.6M1.62M
2026-02-133.42%0.1M2.6M1.61M
2026-01-3030.15%0.8M2.6M1.57M
2026-01-150.33%0.0M2.6M478.18K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-168-KCurrent report2026-10-13SEC
2026-10-068-KCurrent report2026-09-30SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-08-21ARSAnnual report to security holders. 2026-03-31SEC
2026-08-218-KCurrent report2026-08-17SEC
2026-08-21DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-30SEC
2026-08-17SCHEDULE 13G/ASEC
2026-08-13PRER14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-10EFFECTEffectiveness filing by commission orderSEC
2026-08-10PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-31S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-07-308-KCurrent report2026-07-30SEC
2026-07-248-KCurrent report2026-07-20SEC
2026-07-178-KCurrent report2026-07-16SEC
2026-07-1410-KAnnual report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-06-29NT 10-K2026-03-31SEC
2026-04-06SCHEDULE 13GSEC
2026-04-038-KCurrent report2026-03-31SEC
2026-04-02424B4SEC
2026-03-31EFFECTEffectiveness filing by commission orderSEC
2026-03-31CORRESPSEC
2026-03-31CORRESPSEC
2026-03-31S-1/ASEC
2026-03-30CORRESPSEC
2026-03-30CORRESPSEC
2026-03-27CORRESPSEC
2026-03-27CORRESPSEC
2026-03-27S-1General form of registration statement for all companies including face-amount certificate companiesSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-082.80K100
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
RENAISSANCE TECHNOLOGIES LLC0.71%
HRT FINANCIAL LP0.70%
VANGUARD CAPITAL MANAGEMENT LLC0.59%
BlackRock, Inc.0.45%
VANGUARD FIDUCIARY TRUST CO0.27%
Tower Research Capital LLC0.20%
GEODE CAPITAL MANAGEMENT, LLC0.12%
TRUE Private Wealth Advisors0.07%
UBS Group AG0.05%
FNY Investment Advisers, LLC0.01%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.59%
Fidelity Extended Market Index Fund0.08%
Fidelity Series Total Market Index Fund0.02%
Fidelity Total Market Index Fund0.01%

OakChart. VIVS. Cached 15 minutes.